Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Zealand Pharma A/S Ord (ZLDPF)

Zealand Pharma A/S Ord (ZLDPF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Zealand Pharma A/S Ord Sydmarken 11 Soborg Copenhagen G7 2860 DNK

www.zealandpharma.com Employees: 335 P: 45-8877-3600

Sector:

Medical

INDUSTRY GROUPING:

Medical - Biomedical

Description:

Zealand Pharma A/S is a biotechnology company. It focused on the discovery, design and development of peptide-based medicines. The company's pipeline includes ZP4207, single-dose rescue treatment for acute, severe hypoglycemia; ZP1848 for short bowel syndrome and ZP4207, multiple-dose version intended for use in a dual-hormone artificial pancreas system for better hypoglycemia control and diabetes management and other earlier-stage clinical and preclinical peptide therapeutics are in clinical stage. Zealand Pharma A/S is based in Copenhagen, Denmark.

Key Statistics

Overview:

Market Capitalization, $K 4,534,172
Enterprise Value, $K 4,505,902
Shares Outstanding, K 71,024
Float, K 71,024
% Float 100.00%
Short Interest, K 522
Short Float 0.74%
Days to Cover 327.31
Short Volume Ratio 0.65
% of Institutional Shareholders 0.00%

Financials:

Annual Sales, $ 9,090 K
Annual Net Income, $ -156,430 K
Last Quarter Sales, $ 7,760 K
Last Quarter Net Income, $ -63,300 K
EBIT, $ 1,082 M
EBITDA, $ 1,085 M

Growth:

1-Year Return -36.55%
3-Year Return 124.00%
5-Year Return 0.00%
5-Year Revenue Growth 46.61%
5-Year Earnings Growth 6.72%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.90 on 11/13/25
Next Earnings Date 02/19/26 [--]
Earnings Per Share ttm 13.90
EPS Growth vs. Prev Qtr -105.60%
EPS Growth vs. Prev Year -60.71%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

ZLDPF Ratios

Ratio
Price/Earnings ttm 4.61
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 55.76%
Return-on-Assets % 50.55%
Profit Margin % -1,720.90%
Debt/Equity 0.02
Price/Sales 3.26
Price/Cash Flow N/A
Price/Book 1.92
Book Value/Share 33.43
Interest Coverage -20.03
60-Month Beta 0.72
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar